
Owning the Cancer Treatment and the Plant
For two decades, commercial use of raw acidic cannabinoids sat inside a corporate patent claim. That patent has now expired. But the cancer‑treatment patent built on top of it remains in force, shaping who gets to turn a plant into medicine — and who gets left outside the system.









